<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084134</url>
  </required_header>
  <id_info>
    <org_study_id>201110174</org_study_id>
    <nct_id>NCT02084134</nct_id>
  </id_info>
  <brief_title>Peri-Operative Steroid Management in Patients</brief_title>
  <acronym>Steroid</acronym>
  <official_title>The Use of Perioperative Steroids in Patients Undergoing Transsphenoidal Resection of Pituitary Tumors or Cysts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During transsphenoidal resection of pituitary tumors and cysts, surgery is performed by a
      neurosurgeon and ear nose and throat surgeon. The pituitary tumor or cyst is reached by
      making a small hole in the back of the nose into the bottom of the skull. The surgeon is able
      to see the pituitary and tumor with an endoscope and remove the tumor through the hole.

      Surgery on the pituitary can cause disruption in the secretion of ACTH and cause adrenal
      failure (lack of cortisol secretion) which can cause nausea, vomiting, low blood pressure,
      and rarely can be fatal. There is no consensus among endocrinologists and neurosurgeons about
      the use of perioperative steroids in pituitary patients. Traditionally, all patients
      undergoing pituitary surgery were given steroids before, during, and after surgery because of
      the assumption that there would be some compromise in the amount of ACTH released by the
      pituitary as a result of surgical trauma. Studies have failed to show, however, that ACTH
      secretion is in fact compromised during transsphenoidal pituitary microsurgery. As a result,
      there are some centers that routinely give perioperative steroids to all patients undergoing
      pituitary surgery and there are some centers that do not routinely give perioperative
      steroids. There are several retrospective and prospective studies that have addressed this
      issue and have shown that withholding perioperative steroids is safe, but there has never
      been a prospective study comparing the two approaches.

      Objectives: The goal of this study is to prospectively compare two approaches to the
      perioperative management of patients undergoing transsphenoidal resection of a pituitary
      tumor or cyst. One protocol includes the routine use of perioperative steroids and the other
      does not. The investigators hypothesis, based on previous studies, is that patients who are
      adrenally sufficient do not routinely need to be treated with perioperative steroids. The
      investigators also hypothesize that the use of perioperative steroids may be associated with
      a higher rate of adverse outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are scheduled to undergo transsphenoidal resection for a pituitary tumor or cyst
      at the investigators institution will be screened prior to surgery for eligibility for this
      study. All patients deemed eligible will undergo a cosyntropin stimulation test to evaluate
      for adrenal insufficiency. Patients with adrenal insufficiency will be excluded from the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adrenal Insufficiency</measure>
    <time_frame>6 weeks following surgery</time_frame>
    <description>Adrenal insufficiency was defined by a 30 or 60 min cortisol &lt; 18 during a cosyntropin stimulation test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Discharged on Glucocorticoids</measure>
    <time_frame>1 day (Day of hospital discharge)</time_frame>
    <description>Patient charts were reviewed to identify patients who were discharged on prednisone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pituitary Adenoma</condition>
  <condition>Pituitary Diseases</condition>
  <arm_group>
    <arm_group_label>steroid treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-steroid treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone</intervention_name>
    <description>100mg at the time of surgery</description>
    <arm_group_label>steroid treatment arm</arm_group_label>
    <other_name>intravenous hydrocortisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>0.5mg every 6 hours for a total of four doses</description>
    <arm_group_label>steroid treatment arm</arm_group_label>
    <other_name>intravenous dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult patient with a pituitary adenoma or cyst (either non-functioning, prolactin
             secreting, growth hormone secreting, gonadotropin secreting, or TSH (Thyrotropin
             secreting hormone) scheduled to undergo transsphenoidal resection.

        Exclusion Criteria:

          -  Patients with Cushing's Disease (pituitary tumor which secretes ACTH)

          -  Patients with a history of pituitary apoplexy (condition caused by hemorrhage into a
             pituitary adenoma which causes headache, double vision and hypopituitarism)

          -  Patients on long term glucocorticoid therapy

          -  Patients with adrenal insufficiency or who have not had their adrenal response
             evaluated prior to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M. Silverstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wuphysicians.wustl.edu/physician2.aspx?PhysNum=3867</url>
    <description>Julie M. Silverstein, M.D.</description>
  </link>
  <link>
    <url>https://vfh.wustl.edu/</url>
    <description>Washington University School of Medicine, Research Participant Registry</description>
  </link>
  <reference>
    <citation>Agha A, Liew A, Finucane F, Baker L, O'Kelly P, Tormey W, Thompson CJ. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clin Endocrinol (Oxf). 2004 Jun;60(6):688-93.</citation>
    <PMID>15163331</PMID>
  </reference>
  <reference>
    <citation>Marko NF, Hamrahian AH, Weil RJ. Immediate postoperative cortisol levels accurately predict postoperative hypothalamic-pituitary-adrenal axis function after transsphenoidal surgery for pituitary tumors. Pituitary. 2010 Sep;13(3):249-55. doi: 10.1007/s11102-010-0227-6.</citation>
    <PMID>20339931</PMID>
  </reference>
  <reference>
    <citation>Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ. Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation. J Neurosurg. 2009 Sep;111(3):540-4. doi: 10.3171/2008.12.JNS081265.</citation>
    <PMID>19326985</PMID>
  </reference>
  <reference>
    <citation>Hout WM, Arafah BM, Salazar R, Selman W. Evaluation of the hypothalamic-pituitary-adrenal axis immediately after pituitary adenomectomy: is perioperative steroid therapy necessary? J Clin Endocrinol Metab. 1988 Jun;66(6):1208-12.</citation>
    <PMID>3372683</PMID>
  </reference>
  <reference>
    <citation>Bhansali A, Dutta P, Bhat MH, Mukherjee KK, Rajput R, Bhadada S. Rational use of glucocorticoid during pituitary surgery--a pilot study. Indian J Med Res. 2008 Sep;128(3):294-9.</citation>
    <PMID>19052341</PMID>
  </reference>
  <reference>
    <citation>Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J Clin Endocrinol Metab. 2002 Jun;87(6):2745-50. Review.</citation>
    <PMID>12050244</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>January 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2018</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pituitary adenoma</keyword>
  <keyword>Pituitary Tumor</keyword>
  <keyword>transsphenoidal resection</keyword>
  <keyword>pituitary cyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Steroid Treatment Arm</title>
          <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
hydrocortisone: 100mg at the time of surgery
dexamethasone: 0.5mg every 6 hours for a total of four doses</description>
        </group>
        <group group_id="P2">
          <title>Non-steroid Treatment</title>
          <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Steroid Treatment Arm</title>
          <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
hydrocortisone: 100mg at the time of surgery
dexamethasone: 0.5mg every 6 hours for a total of four doses</description>
        </group>
        <group group_id="B2">
          <title>Non-steroid Treatment</title>
          <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adrenal Insufficiency</title>
        <description>Adrenal insufficiency was defined by a 30 or 60 min cortisol &lt; 18 during a cosyntropin stimulation test</description>
        <time_frame>6 weeks following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid Treatment Arm</title>
            <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
hydrocortisone: 100mg at the time of surgery
dexamethasone: 0.5mg every 6 hours for a total of four doses</description>
          </group>
          <group group_id="O2">
            <title>Non-steroid Treatment</title>
            <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adrenal Insufficiency</title>
          <description>Adrenal insufficiency was defined by a 30 or 60 min cortisol &lt; 18 during a cosyntropin stimulation test</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Discharged on Glucocorticoids</title>
        <description>Patient charts were reviewed to identify patients who were discharged on prednisone</description>
        <time_frame>1 day (Day of hospital discharge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid Treatment Arm</title>
            <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
hydrocortisone: 100mg at the time of surgery
dexamethasone: 0.5mg every 6 hours for a total of four doses</description>
          </group>
          <group group_id="O2">
            <title>Non-steroid Treatment</title>
            <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Discharged on Glucocorticoids</title>
          <description>Patient charts were reviewed to identify patients who were discharged on prednisone</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Steroid Treatment Arm</title>
          <description>Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
hydrocortisone: 100mg at the time of surgery
dexamethasone: 0.5mg every 6 hours for a total of four doses</description>
        </group>
        <group group_id="E2">
          <title>Non-steroid Treatment</title>
          <description>Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>One patient in non-steroid group died from meningitis which was not felt to be related to the study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Julie Silverstein</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-7006</phone>
      <email>jsilverstein@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

